| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/19/2007 | CA2628863A1 Composition and synthesis of new reagents for inhibition of hiv replication |
| 04/19/2007 | CA2628781A1 Solid dispersions of opioid antagonists |
| 04/19/2007 | CA2628035A1 Composition for improving intestinal microflora |
| 04/19/2007 | CA2627623A1 Methods for inhibiting protein kinases |
| 04/19/2007 | CA2626011A1 S1p3 receptor antagonist |
| 04/19/2007 | CA2625974A1 Imidazole derivatives for the treatment of anxiety and related diseases |
| 04/19/2007 | CA2625819A1 Leucine rich composition |
| 04/19/2007 | CA2625804A1 Pharmaceutical composition based on a morpholinic antimycotic agent and a water-soluble film-forming agent for ungual and periungual application |
| 04/19/2007 | CA2625763A1 Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels |
| 04/19/2007 | CA2625741A1 Treating renal cancer using 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde |
| 04/19/2007 | CA2625731A1 Human microrna targets in hiv genome and a method of identification thereof |
| 04/19/2007 | CA2625687A1 Antibacterial active 5-chinolin derivative |
| 04/19/2007 | CA2625663A1 3,5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission |
| 04/19/2007 | CA2625661A1 Synergistic pharmaceutical composition containing a peptide with 2 to 5 amino acids |
| 04/19/2007 | CA2625642A1 Prolinamide derivatives as sodium channel modulators |
| 04/19/2007 | CA2625620A1 Chitosan and heparin nanoparticles |
| 04/19/2007 | CA2625611A1 Imidazo benzodiazepine derivatives |
| 04/19/2007 | CA2625568A1 Ophthalmic emulsions containing prostaglandins |
| 04/19/2007 | CA2625553A1 Method for treating neuronal and non-neuronal pain |
| 04/19/2007 | CA2625546A1 Diacyl indazol derivatives as lipase and phospholipase inhibitors |
| 04/19/2007 | CA2625532A1 Agent for applying to mucosa containing a hydrophobic group binding type glycosaminoglycan |
| 04/19/2007 | CA2625495A1 Therapeutic agent for nausea and/or vomiting |
| 04/19/2007 | CA2625488A1 Methods and compositions for treating immune disorders |
| 04/19/2007 | CA2625301A1 Isoxazole derivatives |
| 04/19/2007 | CA2625219A1 Heterocyclic compounds as pstat3/il-6 inhibitors |
| 04/19/2007 | CA2625218A1 Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease |
| 04/19/2007 | CA2625150A1 Combined use of dpp-iv inhibitors and gastrin compounds |
| 04/19/2007 | CA2625109A1 Pyrrolopyrimidine derivatives as syk inhibitors |
| 04/19/2007 | CA2625055A1 Novel dihydropseudoerythromycin derivatives |
| 04/19/2007 | CA2625042A1 Iontophoretic preparation for treatment of breast cancer and/or mastitis |
| 04/19/2007 | CA2624965A1 Pyridopyrimidinone inhibitors of pi3k.alpha. |
| 04/19/2007 | CA2624963A1 Microangiopathy treatment and prevention |
| 04/19/2007 | CA2624958A1 Antimitotic rhizoxin derivatives of burkholderia rhizoxina, method for producing said derivatives and use thereof |
| 04/19/2007 | CA2624943A1 Preparation for the treatment of diarrhoea |
| 04/19/2007 | CA2624909A1 Therapeutic agent for treating liver disease containing 2-amino-1,3-propanediol derivative as active ingredient, and method for treating liver disease |
| 04/19/2007 | CA2624902A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 04/19/2007 | CA2624829A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 04/19/2007 | CA2624826A1 Pyrazolopyrimidines as protein kinase inhibitors |
| 04/19/2007 | CA2624825A1 Tacrolimus combination products |
| 04/19/2007 | CA2624822A1 Pyrazolopyrimidines as cyclin dependent kinase inhibitors for the treatment of cancer |
| 04/19/2007 | CA2624719A1 Cathepsin cysteine protease inhibitors |
| 04/19/2007 | CA2624683A1 Modulators of atp-binding cassette transporters |
| 04/19/2007 | CA2624677A1 System and method for the prevention of bacterial and fungal infections including urinary tract infections (uti) using n-halogenated amino acids |
| 04/19/2007 | CA2624619A1 Improved toleration iron supplement compositions |
| 04/19/2007 | CA2624610A1 Kinase inhibitors |
| 04/19/2007 | CA2624584A1 Novel pharmaceutical combinations for the treatment of respiratory disorders |
| 04/19/2007 | CA2624566A1 Chemical compounds |
| 04/19/2007 | CA2624552A1 Process for the synthesis of compounds for selectin inhibition |
| 04/19/2007 | CA2624546A1 Octanol formulations and methods of treatment using the same |
| 04/19/2007 | CA2624519A1 Pyrazolo [1,5-a] pyrimidines as protein kinase inhibitors |
| 04/19/2007 | CA2624500A1 Pyrazolopyrimidines as protein kinase inhibitors |
| 04/19/2007 | CA2624497A1 Antituberculosis drug combination comprising oxazole compounds |
| 04/19/2007 | CA2624440A1 Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| 04/19/2007 | CA2624380A1 Method for manufacturing a monophasic pharmaceutical product for oral therapy of dysfunctional uterine bleeding |
| 04/19/2007 | CA2624333A1 Compounds and methods for inhibiting hepatitis c viral replication |
| 04/19/2007 | CA2624073A1 Formulations of aica riboside |
| 04/19/2007 | CA2624025A1 Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo [3, 4.-b] [1, 4] benzodiazepine |
| 04/19/2007 | CA2623932A1 Prevention of dental plaque and dental calculus in animals |
| 04/19/2007 | CA2623770A1 Pyridopyrimidinone inhibitors of pi3k.alpha. |
| 04/19/2007 | CA2623768A1 N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| 04/19/2007 | CA2623759A1 Pyridopyrimidinone inhibitors of pim 1 and/or pim-3 |
| 04/19/2007 | CA2623535A1 Hexahydro cyclooctyl pyrazole cannabinoid modulators |
| 04/19/2007 | CA2623506A1 Inhibitors of the hiv integrase enzyme |
| 04/19/2007 | CA2623500A1 Kinase inhibitors |
| 04/19/2007 | CA2623327A1 Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| 04/19/2007 | CA2622952A1 Apoe4 domain interaction inhibitors and methods of use thereof |
| 04/19/2007 | CA2622754A1 N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors |
| 04/19/2007 | CA2622464A1 Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment |
| 04/19/2007 | CA2621038A1 Triarylcarboxylic acid derivative |
| 04/19/2007 | CA2620899A1 Benzoxazoles useful in the treatment of inflammation |
| 04/19/2007 | CA2620363A1 Naphthalene-disulfonamides useful for the treatment of inflammation |
| 04/19/2007 | CA2620308A1 Crystalline forms of docetaxel and processes for their preparation |
| 04/19/2007 | CA2619476A1 Separation of fulvestrant isomers |
| 04/19/2007 | CA2608201A1 Heterocyclic inhibitors of mek and methods of use thereof |
| 04/19/2007 | CA2588833A1 Compositions having a high antiviral and antibacterial efficacy |
| 04/18/2007 | EP1775305A2 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 04/18/2007 | EP1775303A1 Topiramate and pharmaceutical compositions thereof |
| 04/18/2007 | EP1775302A1 Method for preparing crystalline sodium risedronate |
| 04/18/2007 | EP1775300A1 Process for production of polysubstituted cyclobutanes and polysubstituted cyclobutenes |
| 04/18/2007 | EP1775298A1 Thienopyrazole derivative having pde7 inhibitory activity |
| 04/18/2007 | EP1775297A2 Adenosine receptor antagonists and methods of making and using the same |
| 04/18/2007 | EP1775294A1 Phenyl-furyl-methyl-thiazolidine-2,4-dione or phenyl-thienyl-methyl-thiazolidine-2,4-dione compounds; use for stimulating or inducing keratin fibre growth and/or slowing down their loss; compostions thereof |
| 04/18/2007 | EP1775293A1 Antiplatelet agent and process for producing the same |
| 04/18/2007 | EP1775292A1 Salts of benzimidazole derivative with amines and process for production thereof |
| 04/18/2007 | EP1775289A1 Novel imidazolidine derivatives |
| 04/18/2007 | EP1775288A1 Delta d Crystaline form of ivabradine hydrochloride, process of preparation thereof and pharmaceutical compositions containing the same |
| 04/18/2007 | EP1775287A1 Delta d Crystaline form of ivabradine hydrochloride, process of preparation thereof and pharmaceutical compositions containing the same |
| 04/18/2007 | EP1775286A1 Novel anandamide amidase inhibitors as analgesic agents |
| 04/18/2007 | EP1775283A1 3-aminobenamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
| 04/18/2007 | EP1774974A1 Use of hyperforin or St. John's Wort in the treatment and prevention of metabolic syndrome |
| 04/18/2007 | EP1774971A1 Chitosan and heparin nanoparticles |
| 04/18/2007 | EP1774970A1 Method for preparing a monophase pharnmaceutical preparation containing ethinyl estradiol and dienogest for the treatment of dysfunctional uterine bleeding |
| 04/18/2007 | EP1774969A2 Controlled release oxycodone compositions |
| 04/18/2007 | EP1774968A1 Benzylisoquinoline derivative- or bisbenzylisoquinoline derivative-containing psychotropic agent, analgesic and/or antiphlogistic, and health food |
| 04/18/2007 | EP1774967A1 Solid oral dosage forms comprising valsartan |
| 04/18/2007 | EP1774966A1 Inhibitor for the onset and progress of liver cancer to be used in hepatitis c virus-positive human liver cirrhosis patients |
| 04/18/2007 | EP1774965A2 Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
| 04/18/2007 | EP1774964A1 Nicotine transdermal preparation and production method thereof |
| 04/18/2007 | EP1774961A2 Methods for stabilizing ophthalmic compositions |
| 04/18/2007 | EP1774959A1 Double stranded RNA oligonucleotide to inhibit tyrosinase expression |